Salarius Pharmaceuticals Inc.
08/26/2025 | Press release | Distributed by Public on 08/26/2025 15:29
Material Event (Form 8-K)
Item 8.01. Other Events.
On August 22, 2025, Salarius Pharmaceuticals, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to its effective registration statement on Form S-3 (File No. 333-266589) (the "Registration Statement"), filed with the U.S. Securities and Exchange Commission on August 5, 2022 and declared effective by the SEC on August 16, 2022, covering the registered offering of up to $2,600,000 of shares of common stock, par value $0.0001 per share, of the Company (the "Shares"), pursuant to the At the Market Offering Agreement, dated as of February 5, 2021, with Ladenburg Thalmann & Co. Inc.
In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.
Salarius Pharmaceuticals Inc. published this content on August 26, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on August 26, 2025 at 21:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]